Key statistics
On Wednesday, Cassava Sciences Inc (SAVA:NAQ) closed at 2.15, 86.96% above the 52 week low of 1.15 set on Apr 10, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.17 |
|---|---|
| High | 2.19 |
| Low | 2.09 |
| Bid | -- |
| Offer | -- |
| Previous close | 2.18 |
| Average volume | 627.13k |
|---|---|
| Shares outstanding | 48.31m |
| Free float | 42.13m |
| P/E (TTM) | -- |
| Market cap | 105.31m USD |
| EPS (TTM) | -2.20 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Announcements
- Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
- Cassava Announces Agreement to Settle Securities Class Action Litigation
- Cassava Reports Q3 2025 Financials Results and Provides Business Update
- Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
- Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
- Cassava Reports Q2 2025 Financials Results and Provides Business Update
- Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
- Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
- Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
- Cassava Reports Q1 2025 Financials Results, Provides Business Update
More ▼
